UPnRIDE Power Standing Wheelchair for SCI

Spinal Cord Injuries Clinical Trial

Official title:

Evaluation of an Upright Powered Wheelchair for People With SCI

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04163796
• Other study ID #: SPU-17-036
• Status: Completed
• Phase: N/A
• Start date: August 1, 2018
• Est. completion date: December 30, 2023

Study information

• Verified date: January 2024
• Source: Bronx Veterans Medical Research Foundation, Inc
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

People with higher level of spinal cord injury have limitations to using exoskeletal-assisted walking devices due to restrictions of trunk stability, functional use of the upper extremities and hand grip. With increasing sedentary time in wheelchairs, people with SCI have a high risk for developing secondary complications. A powered wheelchair has recently been developed for use in persons with spinal cord injury that provides a solution for placing the user in an upright, standing position while maintaining the overground mobility features of the powered wheelchair; providing the ability to engage in society in either a standing or seated position. The purpose of this study is to verify user performances of the upright powered wheelchair and to identify obstacles that are difficult, or prevent use. Additionally, the option to have upright posture throughout the day may have the potential to improve some of the secondary medical conditions associated with the extreme sedentary lifestyle.

This study will determine change from baseline after 12 weeks of use for safety, tolerance, medical, physical and quality of life outcomes. The intervention will consist of 3.5 hours per session, 3 times per week for 12 weeks. During each session, participants will be asked to stand at least 5 minutes during every 15 minutes. To our knowledge, there is no existing empirical data on intermittent standing during the day in persons with higher levels of SCI who cannot otherwise stand and whether this approach will improve health related outcomes.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 5
• Est. completion date: December 30, 2023
• Est. primary completion date: December 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 89 Years

Eligibility

Inclusion Criteria:

1. Power wheelchair user as a primary means of mobility;

2. 18-89 years old;

3. =1 year after SCI;

4. Height of 160 to 190 cm;

5. Weight of <100 kg; and

6. Able to sign informed consent.

Exclusion Criteria:

1. Able to ambulate with or without an assistive device or physical assistance greater than 4 consecutive steps;

2. Any pressure ulcer at any body location that is deemed to be contraindicated for a power wheelchair or standing frame by the study physician;

3. Concurrent medical disease that would be exclusionary for standing (as per the clinical judgment of the study physician);

4. Severe spasticity (Ashworth 4) or uncontrolled clonus;

5. History of fragility fractures, long bone fractures in the past 1 years, heterotrophic ossification, or other bone conditions that would be exclusionary for use of a standing modality as per the clinical judgment of the study physician;

6. Significant contractures that would be exclusionary for use of a standing modality as per the clinical judgment of the study physician

7. Psychiatric or cognitive status that may interfere with the ability to follow instruction to use the device; and

8. Pregnant or lactating women.

Related Conditions & MeSH terms

• Spinal Cord Injuries

Intervention

Device:
• UPnRIDE power wheelchair
The intervention will consist of approximately 3.5 hours per session, 3 times per week over 12 weeks. During each 3.5-hour session, subjects will be asked to stand at least 5 minutes during every 15 minutes or more as tolerated. One time each session, participants will be asked to perform the Activities of Daily Living course.

Locations

Country	Name	City	State
United States	Spinal Cord Damage Research Center	Bronx	New York

Sponsors (1)

Lead Sponsor	Collaborator
Bronx Veterans Medical Research Foundation, Inc

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Wheelchair mobility skills - RPE	Participants will be requested to perform a rating of perceived exertion (RPE).	Training Period - 36 Sessions up to 12 weeks
Primary	Wheelchair mobility skills - FIM	Participants will be requested to perform a rating Functional Independence Measurement (FIM) for each UPnRIDE activity.	Training Period - 36 Sessions up to 12 weeks
Primary	Activities Daily Living Course - RPE	Participants will be requested to perform a rating of perceived exertion (RPE) during the Activities Daily Living Course (ADLC).	Training Period - 36 Sessions up to 12 weeks
Primary	Activities Daily Living Course - FIM	Participants will be requested to perform a rating Functional Independence Measurement (FIM) during the Activities Daily Living Course (ADLC).	Training Period - 36 Sessions up to 12 weeks
Secondary	Postural orthostatic hypotension blood pressure tolerance test (OH BP)	Participants will be in the supine position on a bed or elevated gym mat and beat-to-beat HR will be recorded for 60 seconds, followed by passive re-positioning to the seated position on a bed or elevated gym mat with the hip and knee at a 90° angle and the lower leg hanging off the side. Passive repositioning will be accomplished by one staff member lifting the participant's torso by the shoulders, while supporting the head and neck, and a second staff member shifting the subject perpendicular to the bed and allowing the participant's legs to hang off the side. Participants will be instructed not to assist in the passive movement during this transition, and will be supported by staff.	Evaluations - Baseline/After session 18 (up to 6 weeks) /After session 36 (up to 12 weeks)
Secondary	Pulmonary function tests - Spirometry	While seated in the chair and after a mouth piece and nose clip are applied, the subject will be asked to breathe normally for 3 to 6 breaths. They will then be instructed to forcibly inhale until their lungs are filled. After a brief pause, they will then be instructed to forcibly exhale the air in their lungs and hold the maneuver for approximately 6 seconds. After a brief rest, the maneuver will be repeated a minimum of three times to ensure reliability.	Evaluations - Baseline/After session 18 (up to 6 weeks) /After session 36 (up to 12 weeks)
Secondary	Pulmonary function tests - Static Lung Volumes	The volume of air in the lungs will be assessed using the nitrogen washout technique. The nitrogen washout technique, which takes about five minutes to perform, will begin while a subject is seated in his/her wheelchair and after a mouth piece and nose-clips have been applied. The subject will then be asked to breathe room air into and out of the mouthpiece for 3-6 breaths. The air exhaled, which normally contains mostly nitrogen, will be collected and analyzed by the pulmonary function cart. Once a participant has completed the 3-6 breaths, s/he will be asked to take a slow deep breath in and to exhale until the lungs are empty, after which the participant returns to a normal breathing pattern. Following an additional 3-6 regular breaths, the pulmonary function cart will begin delivering 100% oxygen through the mouthpiece. The subject will continue to inhale 100% oxygen while taking normal breaths until oxygen is the only gas measurable in his/her exhaled air.	Evaluations - Baseline/After session 18 (up to 6 weeks) /After session 36 (up to 12 weeks)
Secondary	Pulmonary function tests - Breathing Pattern	Resting breathing pattern will be measured by abdominal and thoracic respiratory inductive plethysmography. The participant will be asked to wear two chest straps for a designated period of time. Signals from the participant's chest wall excursions are analyzed for indices of resting breathing pattern such as tidal volume and timing and derivatives of these measurements.	Evaluations - Baseline/After session 18 (up to 6 weeks) /After session 36 (up to 12 weeks)
Secondary	Inflammatory biomarkers	Due to its clinical utility and widespread use to measure risks for coronary heart disease, the primary outcome assessment of systemic inflammation will be levels of CRP, which will be measured in sera using a commercially available ELISA. Additional exploratory analyses may be performed using commercially available single- and multi-plex immunoassays to assay the following: HMGb1, IL-1ß, IL-1Ra, IL-6, IL-8, IL-10, IL-15, MIF, MIP1-a/CCL3, TNF-a, leptin, and adipokine.	Evaluations - Baseline/After session 18 (up to 6 weeks) /After session 36 (up to 12 weeks)
Secondary	Body Composition	A dual energy x-ray absorptiometry (DXA) scan for regional and total body fat, lean and bone tissue masses will be performed two times: at baseline and post.	Evaluations - Baseline/After session 18 (up to 6 weeks) /After session 36 (up to 12 weeks)
Secondary	Bowel function surveys - 10Q Bowel Function Survey (BFS)	The 10Q Bowel Function Survey (BFS) will be administered three times: at baseline, midpoint, and post.	Evaluations - Baseline/After session 18 (up to 6 weeks) /After session 36 (up to 12 weeks)
Secondary	Bowel function surveys - Bristol Stool Scale	The Bristol Stool Scale (BSS) will be administered three times: at baseline, midpoint, and post. The BSS is a diagnostic medical tool designed to classify the form of human faces into seven categories (Type 1 to 7: Hard lumps to Soft/Liquid).	Evaluations - Baseline/After session 18 (up to 6 weeks) /After session 36 (up to 12 weeks)
Secondary	SCI-QOL	The Spinal Cord Injury Quality of Life measurement tool is the first validated SCI-specific QOL measurement tool for the field. The specific short form item banks to be use are: Bowel and Bladder Management Difficulties from the Physical Medical Domain, Ability to Participate and Independence from the Social Domain, and Positive Affect, and Resilience from Emotional Domain. These will be performed three times: at baseline, midpoint, and post.	Evaluations - Baseline/After session 18 (up to 6 weeks) /After session 36 (up to 12 weeks)
Secondary	Lipid Profile - Cholesterols	Total cholesterol (TC), low density lipoprotein cholesterol (LDL-c), triglyceride (TG) and high density lipoprotein cholesterol (HDL-c) values will be measure and samples will be collected at baseline, midpoint and post.	Evaluations - Baseline/After session 18 (up to 6 weeks) /After session 36 (up to 12 weeks)
Secondary	Homeostatic Model of Insulin Resistance (HOMA-IR)	The standard equation for the HOMA-IR will be used to calculate insulin resistance [HOMA-IR = FPG (mg/dl) x FPI(µU/mL) / 405].	Evaluations - Baseline/After session 18 (up to 6 weeks) /After session 36 (up to 12 weeks)
Secondary	Serum total testosterone levels	Serum total testosterone will be determined by a radioimmunoassay (RIA; MP Biomedicals, Costa Mesa, CA) kit with an intra-assay CV of 10.0, 9.6, and 13% at 1.4, 4.6, and 8.0 nmol/L41,61,62. Measurements will be performed pre, midpoint and post.	Evaluations - Baseline/After session 18 (up to 6 weeks) /After session 36 (up to 12 weeks)
Secondary	Serum estradiol levels	Serum estradiol values will be determined by a commercial kit assay using RIA (MP Biomedicals, Costa Mesa, CA) with an intra-assay CV of 15.7, 5.5, and 3.5% at 25.4, 152, and 657 pg/mL63. Measurements will be performed pre, midpoint and post.	Evaluations - Baseline/After session 18 (up to 6 weeks) /After session 36 (up to 12 weeks)
Secondary	Lower extremity blood flow	Lower extremity blood flow will be measured by strain gauge and will be assessed at sessions 1 and 36.	Evaluations - Baseline/After session 18 (up to 6 weeks) /After session 36 (up to 12 weeks)